

Catalyst Pharmaceuticals, Inc. Investor Relations Department 355 Alhambra Circle Suite 1250 Coral Gables, FL 33134 United States

Visit IR website ☐ Sign-up for email alerts ☐ ☐

NASDAQ: CPRX ¹

Last Trade:	3.08
Trade Time:	4:00 PM ET 07/24/17
Change:	0.13 👚 (4.407%)
Day Range	2.92 - 3.10
52-Week Range	0.68 - 3.16
Volume	846,828
Market Cap. (\$M)	260.445
Shares Out (M)	84.560

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, amifampridine phosphate, for the treatment of LEMS has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data. Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and Congenital Myasthenic Syndromes (CMS). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

... (more)

Stock Performance



Press Releases [View all]

06/26/17

Catalyst Pharmaceuticals Joins Russell 3000 Index

06/01/17

<u>Catalyst Pharmaceuticals to Present at the</u> Jefferies 2017 Healthcare Conference

05/17/17

Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium

05/12/17

Catalyst Pharmaceuticals Receives 2017

Beacon Council Award for Contributions in

Life Sciences & Healthcare

05/10/17

Catalyst Pharmaceuticals Announces First
Quarter 2017 Financial Results and Provides
Corporate Update

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

03/15/17

Annual Report (10-K)

04/14/17

Definitive Proxy Statement

05/10/17

Quarterly Report (10-Q)

11/09/16

Quarterly Report (10-Q)

08/09/16

Quarterly Report (10-Q)

